We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Tapentadol Versus Oxycodon - a Mechanism-based Treatment Approach in Neuropathic Pain

This study has been terminated.
Sponsor:
ClinicalTrials.gov Identifier:
NCT01458015
First Posted: October 24, 2011
Last Update Posted: March 26, 2014
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
Ralf Baron, University of Schleswig-Holstein
  Purpose
The purpose of this study is to elucidate whether the additional mechanism of analgesia, i.e. reuptake inhibition of norepinephrine, of tapentadol leads to a change in different pain signs and symptoms in comparison to oxycodone.

Condition Intervention Phase
Peripheral Neuropathy Drug: tapentadol, oxycodone Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Official Title: Phase 4 Study of Tapentadol vs Oxycodone in Neuropathic Pain

Resource links provided by NLM:


Further study details as provided by Ralf Baron, University of Schleswig-Holstein:

Primary Outcome Measures:
  • QST parameters on mechanical and thermal thresholds (detailed below) [ Time Frame: day 0 (baseline) and day 78 (10 weeks) ]
    change from baseline in mechanical and thermal pain thresholds and sensitivity measured by QST

  • mechanical pain threshold (MPT) [ Time Frame: day 0 (baseline) and day 78 (10 weeks) ]
  • mechanical pain sensitivity (MPS) [ Time Frame: day 0 (baseline) and day 78 (10 weeks) ]
  • dynamic mechanicl allodynia (DMA) [ Time Frame: day 0 (baseline) and day 78 (10 weeks) ]
  • wind-up ratio (WUR) [ Time Frame: day 0 (baseline) and day 78 (10 weeks) ]

Enrollment: 5
Study Start Date: October 2011
Study Completion Date: November 2013
Primary Completion Date: November 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: oxycodone Drug: tapentadol, oxycodone
tapentadol pr 100-500 mg oxycodone cr 20-120mg
Other Name: Palexia
Active Comparator: tapentadol Drug: tapentadol, oxycodone
tapentadol pr 100-500 mg oxycodone cr 20-120mg
Other Name: Palexia

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • thermal or mechanical hyperalgesia
  • chronic neuropathic pain (NRS => 6)

Exclusion Criteria:

  • non-specific
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01458015


Locations
Germany
Division for Neurological Pain Research and Therapy
Kiel, Schleswig Holstein, Germany, 24105
Sponsors and Collaborators
University of Schleswig-Holstein
Investigators
Principal Investigator: Ralf Baron, Prof. Dr. Head of Unit of Neuropathic Pain Research and Therapy, Department of Neurology, University Clinic Kiel
  More Information

Responsible Party: Ralf Baron, Prof. Dr. med., University of Schleswig-Holstein
ClinicalTrials.gov Identifier: NCT01458015     History of Changes
Other Study ID Numbers: TapOxy01
First Submitted: August 5, 2011
First Posted: October 24, 2011
Last Update Posted: March 26, 2014
Last Verified: March 2014

Keywords provided by Ralf Baron, University of Schleswig-Holstein:
QST
neuropathic pain
tapentadol pr
oxycodone

Additional relevant MeSH terms:
Neuralgia
Peripheral Nervous System Diseases
Pain
Neurologic Manifestations
Nervous System Diseases
Neuromuscular Diseases
Signs and Symptoms
Oxycodone
Analgesics, Opioid
Narcotics
Central Nervous System Depressants
Physiological Effects of Drugs
Analgesics
Sensory System Agents
Peripheral Nervous System Agents